VEGFA and neoplasm: Therefore, it can be considered that lenvatinib reduces tumor vascular permeability and interstitial pressure by inhibiting VEGF and FGFR signaling pathways, thereby improving the intratumoral delivery of TAS-102 and enhancing its DNA damage-induced apoptosis.